Categories: News

Comment on the interview for the journal Dienas Bizness

Comment on the interview for the journal Dienas Bizness

The Management Board of  “Olainfarm” got acquainted with the interview with Roberts Tavjevs, Member of the Board of the largest shareholder AS “AB CITY”, who controls 50.93% of the company’s voting capital, for the journal Dienas Bizness, which provides information on future plans for “Olainfarm”, including the perspective of profit distribution, namely, that no dividends are planned to be paid in the next five years.

The Management Board of “Olainfarm” informs that the above-mentioned is contrary to the dividend policy approved by the Council of “Olainfarm”. At the same time, it should be noted that only the shareholders’ meeting has the right to decide on the amount of dividends to be paid to “Olainfarm” shareholders.

Changes to the dividend policy, if necessary, shall be prepared by the Management Board and submitted to the Council for approval when necessary.

Additional information:  
Jānis Leimanis
JSC Olainfarm Member of Management Board
Phone: +371 29269424
Email: janis.leimanis@olainfarm.com

Staff

Recent Posts

HeartBeam to Attend JP Morgan 2025 Annual Healthcare Conference

HeartBeam system was recently cleared by US Food and Drug Administration (FDA) for comprehensive arrhythmia…

2 hours ago

Glaukos Submits New Drug Application to U.S. FDA for Epioxa™

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused…

2 hours ago

The National Children’s Cancer Society Awarded $1,000 Grant From Kars4Kids

This generous grant will directly benefit the NCCS's Beyond the Cure Ambassador Scholarship Program, which…

2 hours ago

Honeycomb Clinic Positions for Public Offering

Medical Co-working space challenges broken healthcare system. HOUSTON, TEXAS / ACCESSWIRE / December 23, 2024…

2 hours ago

Ensysce Biosciences Regains Full Compliance with Nasdaq

SAN DIEGO, CALIFORNIA / ACCESSWIRE / December 23, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce"…

2 hours ago